HighTower Advisors
AKTX

HighTower Advisors’s Akari Therapeutics AKTX Stock Holding History

HighTower Advisors’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,981
Closed -$22.9K – 3804
2025
Q4 		$22.9K Hold
1,981
– – ﹤0.01% 3607
2025
Q3 		$80K Hold
1,981
– – ﹤0.01% 3570
2025
Q2 		$92.7K Buy
+1,981
New +$99.9K ﹤0.01% 3479
2021
Q4 		– Sell
-25
Closed -$33K – 3288
2021
Q3 		$33K Sell
25
-8
-24% -$10.9K ﹤0.01% 2971
2021
Q2 		$45K Buy
+33
New +$52.8K ﹤0.01% 2901
2021
Q1 		– Sell
-33
Closed -$49K – 3042
2020
Q4 		$49K Buy
33
+13
+65% +$18K ﹤0.01% 2412
2020
Q3 		$27K Buy
+20
New +$29.7K ﹤0.01% 2350
2020
Q2 		– Sell
-20
Closed -$24K – 2427
2020
Q1 		$24K Sell
20
-25
-56% -$34.8K ﹤0.01% 2066
2019
Q4 		$64K Buy
45
+26
+137% +$38.3K ﹤0.01% 2110
2019
Q3 		$25K Buy
+19
New +$29.1K ﹤0.01% 2255
2015
Q1 		– Sell
-2
Closed -$66K – 1607
2014
Q4 		$66K Sell
2
-2
-50% -$87.6K ﹤0.01% 1490
2014
Q3 		$179K Hold
4
– – ﹤0.01% 1367
2014
Q2 		$186K Buy
+4
New +$183K ﹤0.01% 1418

Other funds holding AKTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return

HighTower Advisors's AKTX Position: Q1 2026 in Review

HighTower Advisors sold out of Akari Therapeutics (AKTX) in Q1 2026, closing a stake of 1,981 shares — an estimated $22.9K sold.

HighTower Advisors first reported a position in AKTX in Q2 2014 and held it in 13 quarters. The position peaked at $186K in Q2 2014. 6 funds tracked by Wall St. Rank hold AKTX as of Q1 2026.

  • HighTower Advisors reported no remaining Akari Therapeutics position as of Q1 2026 after selling out during the quarter.
  • HighTower Advisors sold 1,981 Akari Therapeutics shares in Q1 2026, an estimated $22.9K.
  • HighTower Advisors first reported a position in Akari Therapeutics in Q2 2014 and held it in 13 quarters.
  • HighTower Advisors's Akari Therapeutics position peaked at $186K in Q2 2014.
  • 6 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.